The Jab1/COP9 signalosome subcomplex is a downstream mediator of Bcr-Abl kinase activity and facilitates cell-cycle progression
- 15 January 2005
- journal article
- Published by American Society of Hematology in Blood
- Vol. 105 (2) , 775-783
- https://doi.org/10.1182/blood-2004-04-1242
Abstract
Jab1 is a multifunctional protein associated with the signaling pathway, cell-cycle regulation, and development, and acts as a key subunit of COP9 signalosome (CSN). Jab1 promotes degradation of the cyclin-dependent kinase inhibitor p27Kip1 by transportation from the nucleus to the cytoplasm. However, there has been no clear evidence for whether and how Jab1 contributes to malignant transformation in human cancers. Here we show that Bcr-Abl tyrosine kinase facilitates the down-regulation of p27 by modulating complex formation of Jab1/CSN through the mitogen-activated protein (MAP) kinase and phosphatidylinositol 3 (PI3) kinase signaling pathways. Nearly half of the chronic myelogenous leukemia cell lines and the murine hematopoietic precursor cells expressing Bcr-Abl exhibited a marked increase in the small loose Jab1 complex located in the cytoplasm. Inhibition of Bcr-Abl kinase by STI571 induced G1 arrest and caused a recovery of the p27 level with reduction of the small Jab1 complex from the cytoplasm. Either blockade of the MAP kinase and PI3 kinase pathways by specific inhibitors or Jab1 knockdown by small interfering RNA (siRNA) prevented p27 down-regulation as well as formation of the small complex. Thus, regulation of p27 via modulation of the Jab1 subcomplex is a novel mechanism whereby Bcr-Abl oncogenic signals accelerate abnormal cell proliferation.Keywords
This publication has 47 references indexed in Scilit:
- Modeling Philadelphia chromosome positive leukemiasOncogene, 2001
- CDK inhibitors: positive and negative regulators of G1-phase progressionGenes & Development, 1999
- Signaling Pathways Activated by Oncogenic Forms of Abl Tyrosine KinaseJournal of Biological Chemistry, 1999
- Chronic Myeloid LeukemiaNew England Journal of Medicine, 1999
- Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomasNature Medicine, 1997
- Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancerNature Medicine, 1997
- Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patientsNature Medicine, 1997
- Cancer Cell CyclesScience, 1996
- Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitroScience, 1992
- In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome.Proceedings of the National Academy of Sciences, 1987